Cultivation Capital Life Sciences
Cultivation Capital Life Sciences is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Cultivation Capital Life Sciences.
Cultivation Capital Life Sciences is a company.
Key people at Cultivation Capital Life Sciences.
Key people at Cultivation Capital Life Sciences.
Cultivation Capital Life Sciences & Health Technology is a dedicated investment strategy within Cultivation Capital, a venture capital firm founded in 2012 that manages funds focused on early-stage startups.[1][2][4] Its mission aligns with the firm's broader vision of advancing entrepreneurs through capital, counsel, and networks while fostering thriving enterprises and vibrant communities, with a philosophy centered on putting entrepreneurs first, leading investments (about half of rounds), and providing active operating support via board roles.[1][2] Key sectors include therapeutics, diagnostics, research tools and reagents, medical devices, and healthcare IT, with emphasis on digital health innovations like remote care, hospital efficiency, supply chain, and clinical research—areas highlighted by COVID-19 gaps.[4] The firm impacts the startup ecosystem by investing $250k–$1M initially (post-seed/pre-Series A) in companies across 25+ states/countries, earning recognition as one of North America's most active early-stage VCs and top U.S. lead investors per Crunchbase.[1][4]
Cultivation Capital was founded in 2012 in St. Louis, Missouri, as a venture capital firm targeting early-stage companies with transformative potential.[1][5] Key partners include General Partners Andy Dearing, Barry Sandweiss, Bill Schmidt, and Dr. Bobby W. Sandage, who bring seasoned entrepreneurial and investment experience to guide portfolio growth and exits.[5] The Life Sciences & Health Technology strategy evolved as one of the firm's core focuses alongside software/IT, agtech, and geospatial tech, with the healthcare team actively investing in early-stage life sciences since inception and adapting to post-COVID digital health needs.[1][2][4] This evolution reflects a commitment to global, inclusive investing in promising founders regardless of location.[1]
Cultivation Capital Life Sciences rides the wave of advancing life sciences innovation, capitalizing on post-COVID accelerations in digital health, remote care, and supply chain efficiencies amid rising demand for therapeutics, diagnostics, and medtech.[4] Timing is ideal as early-stage funding gaps persist for post-seed/pre-Series A companies, where the firm provides critical $250k–$1M bridges to scale; market forces like aging populations, biotech breakthroughs, and healthcare digitization favor its focus.[1][4] It influences the ecosystem by building inclusive portfolios across 25+ locations, nurturing Midwest startups (e.g., via dedicated seed funds), and fostering community impact through entrepreneur-first collaborations that drive exits and regional vibrancy.[1][2]
With 4 funds in market as of mid-2025 (openings in Apr-Jun 2025), Cultivation Capital Life Sciences is poised to deepen its digital health push, targeting sustained gaps in clinical research and hospital tech amid ongoing AI-biotech convergence.[4][5] Trends like precision medicine and sustainable health innovations will shape its trajectory, potentially expanding geospatial-health intersections. Its influence may evolve by leading more global, diverse deals, amplifying Midwest as a life sciences hub while exceeding LP expectations through proven active support—reinforcing its role in transforming how we live and work via thriving startups.[1][2]
